SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Diversa Corporation (DVSA) -- Ignore unavailable to you. Want to Upgrade?


To: nigel bates who wrote (31)1/9/2001 10:47:20 AM
From: nigel bates  Read Replies (1) | Respond to of 144
 
Jan. 9 /PRNewswire/ -- Diversa Corporation (Nasdaq: DVSA - news) today announced the issuance of U.S. Patent No. 6,171,820, covering its Gene Site Saturation Mutagenesis (GSSM) technology. This patent expands Diversa's proprietary position in DirectEvolution® technologies and further strengthens Diversa's patent estate, which now consists of 37 issued patents, 8 notices of allowance and over 155 filed patent applications.
Diversa uses the patented GSSM technology to create families of related genes from a parent gene to generate all possible single amino acid substitutions in the expressed protein. Traditional mutagenesis methods typically target a single or limited number of sites for change based upon structural information about the protein. In contrast, GSSM technology enables all possible amino acid codon changes to be made and analyzed, eliminating the need for prior knowledge about the protein structure. The new genes created using GSSM are screened for proteins with desired properties, including characteristics such as functionality at extreme temperatures and pH levels, and increased reaction rates. GSSM can be advantageous in the development of human therapeutic proteins, since this method generates subtle changes to the protein structure that may yield significant improvements in activity and minimize undesired immune responses....